Quanta Therapeutics

What Quanta Therapeutics does

Quanta Therapeutics is a privately held, clinical-stage biopharmaceutical company founded in 2018 and headquartered in South San Francisco, California, with an additional operational site in Radnor, Pennsylvania. The company develops orally bioavailable, allosteric small-molecule inhibitors targeting RAS-driven cancers — specifically KRAS G12D and G12V mutations that account for the majority of KRAS-driven tumors and remain largely undrugged by approved therapies, which target only G12C. The company's discovery engine is built on a proprietary Second Harmonic Generation (SHG) platform, a high-throughput optical technology that measures subtle protein conformational changes and enables functional, structure-based identification of allosteric modulators against previously undruggable signaling complexes.

Quanta's clinical pipeline comprises three Phase 1 programs: QTX3034 (a non-covalent G12D-preferring multi-KRAS inhibitor, including combination with cetuximab), QTX3046 (a non-covalent G12D-selective dual ON/OFF-state inhibitor), and QTX3544 (a G12V-preferring multi-KRAS inhibitor), supported by QTX6255 (pan-KRAS, IND-enabling) and an early RAF1 discovery program targeting RAS-driven tumors via synthetic lethality. In October 2025, the company disclosed positive Phase 1 data for QTX3034 showing favorable safety, confirmed responses in colorectal, pancreatic, and endometrial cancers, and strong molecular responses (>90% G12D ctDNA reduction) both as monotherapy and in combination with cetuximab.

The business model is pre-revenue drug development funded by venture capital. Quanta has raised over $142 million cumulatively across a $32 million seed/Series A (2018), a $60 million Series C (October 2021, co-led by Surveyor Capital and Vida Ventures), and a $50.7 million Series D (May 2023, led by Avidity Partners), with participation from Sofinnova Investments, Longitude Capital, BVF Partners, Logos Capital, AbbVie Ventures, and other investors. The company does not commercialize products today; its investigational therapies are distributed exclusively through US-based Phase 1 clinical trial sites under FDA oversight, with future revenue expected to come from licensing, royalties, or partnership transactions consistent with clinical-stage biopharma norms.

Name

Quanta Therapeutics

Legal name

Quanta Therapeutics, Inc.

Website

https://quantatx.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Quanta Therapeutics is a clinical-stage biopharmaceutical company developing orally bioavailable allosteric small-molecule inhibitors of KRAS G12D and G12V to treat RAS-driven cancers including pancreatic, colorectal, lung, and endometrial tumors.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

SIC

Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAAAIAH

Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

• Allosteric drug discovery
• KRAS inhibitors
• Oncology therapeutics
• Targeted cancer therapy
• Small molecule drugs

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Drug Development and Commercialization: As a clinical-stage biopharmaceutical company, Quanta Therapeutics is focused on developing novel small molecule cancer medicines targeting RAS-driven cancers. The company has no commercialized products yet and is pre-revenue, with operations funded through venture capital financing rounds.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Quanta Therapeutics is a clinical-stage biopharmaceutical company developing orally bioavailable, allosteric small molecule inhibitors targeting KRAS G12D, G12V, and other RAS mutations for the treatment of pancreatic, colorectal, lung, and endometrial cancers. The pipeline includes QTX3034 (G12D-preferring), QTX3046 (G12D-selective), and QTX3544 (G12V-preferring) in Phase 1 trials, plus QTX6255 (pan-KRAS) in IND-enabling activities, supported by a proprietary Second Harmonic Generation (SHG) drug discovery platform.

Product overview

Quanta Therapeutics is developing a pipeline of allosteric small molecule KRAS inhibitors for treating RAS-driven cancers. The company's product portfolio includes three clinically validated candidates: QTX3034 (G12D-preferring multi-KRAS inhibitor in Phase 1), QTX3046 (G12D-selective inhibitor in Phase 1), and QTX3544 (G12V-preferring inhibitor in Phase 1), plus QTX6255 (pan-KRAS in IND-enabling). The pipeline is supported by a proprietary Second Harmonic Generation (SHG) platform technology that enables conformation-based drug discovery. The company also maintains a novel RAF1 discovery program targeting RAS-driven tumors through synthetic lethal mechanisms.

Differentiator

Problem solved

Functional benefit

Products and services

• QTX3034 Non-covalent, potent, orally bioavailable, allosteric multi-KRAS inhibitor with G12D-preferring activity. Currently in Phase 1 clinical trials as monotherapy and in combination with cetuximab for treatment of KRASG12D-mutant solid tumors including pancreatic, colorectal, lung, and endometrial cancers. Favorable safety profile and confirmed responses observed in CRC, PDAC, and endometrial cancer patients.
• QTX3046 Non-covalent, orally bioavailable, KRASG12D-selective, dual ON/OFF state allosteric inhibitor. Currently in Phase 1 clinical trials for treatment of KRASG12D-mutated advanced solid tumors. Designed as a G12D-selective alternative to address distinct patient populations within G12D-mutant cancers.
• QTX3544 Allosteric, orally bioavailable, G12V-preferring, dual ON/OFF state, multi-KRAS inhibitor. Currently in Phase 1 clinical trials for treatment of KRASG12V-driven solid tumors, including colorectal and pancreatic cancers. Addresses the second most prevalent KRAS mutation with no current targeted therapies.
• QTX6255 Pan-KRAS inhibitor in IND-enabling activities, representing a fourth KRAS inhibitor program in Quanta's pipeline and the most broadly active candidate across KRAS mutation subtypes.

Quantifiable outcome

• Phase 1 clinical trial demonstrated favorable safety profile with no dose-limiting toxicities at any dose level and no treatment-related adverse events of grade 3 or greater at RP2D of 1200mg BID.
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Revolution Medicines: Revolution Medicines is a clinical-stage oncology company developing RAS(ON) inhibitors, including the pan-RAS tri-complex inhibitor RMC-6236 and mutant-selective KRAS assets (G12D, G12X). It is the most direct competitor to Quanta because both companies target the same RAS-driven cancer space with non-covalent inhibitors and have multiple clinical programs differentiated by mutation selectivity.
• Mirati Therapeutics (Bristol Myers Squibb): Mirati developed and commercialized KRAZATI (adagrasib), a covalent KRAS G12C inhibitor, before being acquired by Bristol Myers Squibb. It is a direct peer because both companies are KRAS-focused oncology developers pursuing differentiated mutation selectivity and combination strategies in lung and other solid tumors.
• Erasca: Erasca is a clinical-stage precision oncology company developing a pipeline of RAS/MAPK pathway inhibitors, including pan-RAF and ERK inhibitors. It is comparable to Quanta as a similarly sized, similarly capitalized clinical-stage biotech focused exclusively on shutting down the RAS-MAPK signaling axis in cancer.

Broad incumbents

• Amgen: Amgen developed and commercializes Lumakras (sotorasib), the first FDA-approved KRAS G12C inhibitor. As a large oncology incumbent with multiple KRAS combination programs (e.g., Lumakras + panitumumab), Amgen is a comparable peer setting the clinical and commercial benchmark that Quanta's G12D/G12V programs must exceed.
• Genentech (Roche): Genentech is a major oncology incumbent developing KRAS combination strategies (e.g., divarasib with GDC-6036) and other RAS-pathway targeted therapies. It is a comparable broad incumbent peer because it sets the standard for combination regimens that Quanta's allosteric inhibitors will be benchmarked against.
• AstraZeneca: AstraZeneca is a large oncology incumbent that acquired a KRAS G12D program (through the Janssen asset transfer / partnership with Argo Biopharma) and is developing combination strategies in pancreatic and colorectal cancer. It is a comparable broad incumbent peer in the same KRAS-mutant solid tumor indications Quanta targets.

Emerging players

• BridgeBio Pharma: BridgeBio has built a pipeline that includes KRAS program(s) within its oncology subsidiary and pursues genetically defined cancer strategies. It is a relevant emerging peer because both companies target hard-to-drug oncogenic drivers with small molecules backed by strong biological insight.
• Frontier Medicines: Frontier Medicines is developing precision medicines against traditionally undruggable oncology targets, including KRAS, using covalent and chemoproteomic approaches. It is an emerging peer with overlapping scientific ambition (targeting previously undruggable oncoprotein signaling complexes) analogous to Quanta's SHG-based allosteric strategy.
• Foghorn Therapeutics: Foghorn Therapeutics is a clinical-stage oncology company developing precision medicines against chromatin regulatory and previously undruggable cancer targets, with pipeline programs in solid tumors. It is an emerging peer given the similar profile of a platform-driven, clinical-stage biotech tackling hard-to-drug oncology targets with differentiated chemistry.

Others

• Schrödinger: Schrödinger operates a physics-based computational platform for small molecule drug discovery and has internal oncology programs including KRAS collaborations. It is a thematically related peer showcasing an alternative platform-enabled approach to discovering differentiated oncology small molecules.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/quanta-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds4 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quanta Therapeutics